NVAX
Price
$6.84
Change
+$0.24 (+3.64%)
Updated
Dec 3 closing price
Capitalization
1.11B
90 days until earnings call
Intraday BUY SELL Signals
PBYI
Price
$5.19
Change
+$0.32 (+6.57%)
Updated
Dec 3 closing price
Capitalization
261.53M
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVAX vs PBYI

Header iconNVAX vs PBYI Comparison
Open Charts NVAX vs PBYIBanner chart's image
Novavax
Price$6.84
Change+$0.24 (+3.64%)
Volume$3.4M
Capitalization1.11B
Puma Biotechnology
Price$5.19
Change+$0.32 (+6.57%)
Volume$453.22K
Capitalization261.53M
NVAX vs PBYI Comparison Chart in %
View a ticker or compare two or three
VS
NVAX vs. PBYI commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and PBYI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (NVAX: $6.59 vs. PBYI: $4.88)
Brand notoriety: NVAX: Notable vs. PBYI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 31% vs. PBYI: 22%
Market capitalization -- NVAX: $1.11B vs. PBYI: $261.53M
NVAX [@Biotechnology] is valued at $1.11B. PBYI’s [@Biotechnology] market capitalization is $261.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 1 FA rating(s) are green whilePBYI’s FA Score has 1 green FA rating(s).

  • NVAX’s FA Score: 1 green, 4 red.
  • PBYI’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while PBYI’s TA Score has 3 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 5 bearish.
  • PBYI’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than PBYI.

Price Growth

NVAX (@Biotechnology) experienced а -1.49% price change this week, while PBYI (@Biotechnology) price change was -1.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

NVAX is expected to report earnings on Mar 04, 2026.

PBYI is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.11B) has a higher market cap than PBYI($262M). PBYI has higher P/E ratio than NVAX: PBYI (7.01) vs NVAX (3.40). PBYI YTD gains are higher at: 59.836 vs. NVAX (-18.035). NVAX has higher annual earnings (EBITDA): 496M vs. PBYI (63.3M). NVAX has more cash in the bank: 612M vs. PBYI (96M). PBYI has less debt than NVAX: PBYI (49.2M) vs NVAX (228M). NVAX has higher revenues than PBYI: NVAX (1.08B) vs PBYI (238M).
NVAXPBYINVAX / PBYI
Capitalization1.11B262M424%
EBITDA496M63.3M784%
Gain YTD-18.03559.836-30%
P/E Ratio3.407.0149%
Revenue1.08B238M453%
Total Cash612M96M638%
Total Debt228M49.2M463%
FUNDAMENTALS RATINGS
NVAX vs PBYI: Fundamental Ratings
NVAX
PBYI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10017
PRICE GROWTH RATING
1..100
7843
P/E GROWTH RATING
1..100
1147
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (50) in the Biotechnology industry is in the same range as NVAX (75). This means that PBYI’s stock grew similarly to NVAX’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that PBYI’s stock grew similarly to NVAX’s over the last 12 months.

PBYI's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that PBYI’s stock grew significantly faster than NVAX’s over the last 12 months.

PBYI's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for NVAX (78). This means that PBYI’s stock grew somewhat faster than NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for PBYI (47). This means that NVAX’s stock grew somewhat faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXPBYI
RSI
ODDS (%)
Bullish Trend 7 days ago
78%
Bearish Trend 7 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
79%
Bearish Trend 7 days ago
88%
Momentum
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
83%
MACD
ODDS (%)
Bullish Trend 7 days ago
89%
Bullish Trend 7 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 11 days ago
87%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 15 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
77%
Bearish Trend 7 days ago
89%
Aroon
ODDS (%)
Bearish Trend 7 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signal:
Gain/Loss:
PBYI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVHIX5.94N/A
N/A
Nomura High Income Fund Class I
FLACX90.20N/A
N/A
Fidelity Advisor Stock Sel C
SIMYX13.50N/A
N/A
SEI Tax-Managed Intl Mgd Vol Y (SIMT)
LISGX74.09N/A
N/A
ClearBridge Small Cap IS
FMSRX17.44N/A
N/A
MFG Global Sustainable Service

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.49%
MRNA - NVAX
58%
Loosely correlated
-0.41%
BNTX - NVAX
45%
Loosely correlated
-1.42%
XNCR - NVAX
39%
Loosely correlated
-3.15%
FHTX - NVAX
39%
Loosely correlated
-2.50%
CRSP - NVAX
38%
Loosely correlated
-1.13%
More

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with MTNB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-1.71%
MTNB - PBYI
38%
Loosely correlated
+3.77%
DSGN - PBYI
33%
Loosely correlated
+0.11%
HRTX - PBYI
32%
Poorly correlated
+2.61%
NVAX - PBYI
31%
Poorly correlated
-1.49%
VRCA - PBYI
30%
Poorly correlated
-10.79%
More